To identify the prenatal predisposing factors related to neonatal lupus erythematosus (NLE).
Materials and Methods
A retrospective case-control study was made of 131 pregnant women with positive anti-Ro or anti-La autoantibodies and known neonatal outcomes between January 2002 and December 2019 at Siriraj Hospital, Bangkok, Thailand. There were 101 unaffected neonates and 30 NLE cases confirmed postnatally. Demographic and clinical data of the mothers and neonates with and without NLE were statistically compared.
Results
NLE was diagnosed in 30 out of 131 cases. A multivariate analysis identified the following significant factors for NLE: maternal anti-La antibodies (odds ratio (OR), 3.591; p = 0.030); and maternal treatment with either hydroxychloroquine (OR, 0.082; p = 0.001) or prednisolone (OR, 0.136; p = 0.017). Of the significant variables examined in the multivariate analysis models, high levels of maternal anti-La antibodies were found to be the strongest predictor of noncardiac NLE (OR, 4.558; p = 0.032), while a female baby was significantly higher in pregnancies complicated by cardiac NLE (OR, 5.374; p = 0.046). Hydroxychloroquine still provided a protective effect for both cardiac and noncardiac NLE (p = 0.039 and 0.032, respectively).
Conclusions
The maternal anti-La antibodies were a beneficial predictor for NLE, especially as their high titers were influentially associated with noncardiac features. A female fetus seemed to present an increased risk for developing a congenital heart block. Nevertheless, the treatment with hydroxychloroquine during the pregnancies demonstrated a potentially protective factor against both cardiac and noncardiac manifestations.
BuyonJPHiebertRCopelJ, et al.Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol1998; 31(7): 1658–1666.
2.
JaeggiELaskinCHamiltonR, et al.The importance of the level of maternal anti-Ro/SSA antibodies as a prognostic marker of the development of cardiac neonatal lupus erythematosus. J Am Coll Cardiol2010; 55(24): 2778–2784.
3.
VanoniFLavaSAGFossaliEF, et al.Neonatal systemic lupus erythematosus syndrome: a comprehensive review. Clin Rev Allergy Immunol2017; 53(3): 469–476.
TsuboiHSumidaTNomaH, et al.Maternal predictive factors for fetal congenital heart block in pregnant mothers positive for anti-SS-A antibodies. Mod Rheumatol2016; 26(4): 569–575.
8.
CuneoBFBuyonJP. Keeping upbeat to prevent the heartbreak of anti‐Ro/SSA pregnancy. Ultrasound Obstet Gynecol2019; 54(1): 7–9.
9.
IzmirlyPMSaxenaAKimMY, et al.Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus. Circulation2011; 124(18): 1927–1935.
10.
LimayeMABuyonJPCuneoBF, et al.A review of fetal and neonatal consequences of maternal systemic lupus erythematosus. Prenatal Diagn2020; 40: 1066–1076.
11.
LlanosCIzmirlyPMKatholiM, et al.Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors. Arthritis Rheum2009; 60(10): 3091–3097.
12.
IzmirlyPMKimMYLlanosC, et al.Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann Rheum Dis2010; 69(10): 1827–1830.
13.
AmbrosiASalomonssonSEliassonH, et al.Development of heart block in children of SSA/SSB-autoantibody-positive women is associated with maternal age and displays a season-of-birth pattern. Ann Rheum Dis2012; 71(3): 334–340.
14.
TunksRDClowseMEMillerSG, et al.Maternal autoantibody levels in congenital heart block and potential prophylaxis with antiinflammatory agents. Am J Obstet Gynecol2013; 208(1): 64–67.
15.
AnamiAFukushimaKTakasakiY, et al.The predictive value of anti-SS-A antibodies titration in pregnant women with fetal congenital heart block. Mod Rheumatol2013; 23(4): 653–658.
16.
BarsalouJCostedoat-ChalumeauNBerhanuA, et al.Effect of in utero hydroxychloroquine exposure on the development of cutaneous neonatal lupus erythematosus. Ann Rheum Dis2018; 77(12): 1742–1749.
17.
LiYQWangQLuoY, et al.Neonatal lupus erythematosus: a review of 123 cases in China. Int J Rheum Dis2015; 18(7): 761–767.
18.
BuyonJPWinchesterRJSladeSG, et al.Identification of mothers at risk for congenital heart block and other neonatal lupus syndromes in their children. Comparison of enzyme-linked immunosorbent assay and immunoblot for measurement of anti-SS-A/Ro and anti-SS-B/La antibodies. Arthritis Rheum1993; 36(9): 1263–1273.
19.
Martínez-SánchezNPérez-PintoSRobles-MarhuendaÁ, et al.Obstetric and perinatal outcome in anti-Ro/SSA-positive pregnant women: a prospective cohort study. Immunol Res2017; 65(2): 487–494.
20.
SilvermanEMamulaMHardinJA, et al.Importance of the immune response to the Ro/La particle in the development of congenital heart block and neonatal lupus erythematosus. J Rheumatol1991; 18(1): 120–124.
21.
IzmirlyPMLlanosCLeeLA, et al.Cutaneous manifestations of neonatal lupus and risk of subsequent congenital heart block. Arthritis Rheum2010; 62(4): 1153–1157.
22.
KanNSilvermanEDKingdomJ, et al.Serial echocardiography for immune-mediated heart disease in the fetus: results of a risk-based prospective surveillance strategy. Prenat Diagn2017; 37(4): 375–382.
23.
SonessonSEAmbrosiAWahren‐HerleniusM. Benefits of fetal echocardiographic surveillance in pregnancies at risk of congenital heart block: single‐center study of 212 anti‐Ro52‐positive pregnancies. Ultrasound Obstet Gynecol2019; 54(1): 87–95.
24.
FriedmanDMKimMYCopelJA, et al.Prospective evaluation of fetuses with autoimmune-associated congenital heart block followed in the PR Interval and Dexamethasone Evaluation (PRIDE) Study. Am J Cardiol2009; 103(8): 1102–1106.
25.
IzmirlyPSaxenaABuyonJP. Progress in the pathogenesis and treatment of cardiac manifestations of neonatal lupus. Curr Opin Rheumatol2017; 29(5): 467–472.
26.
LiJMHorsfallACMainiRN. Anti-La (SS-B) but not anti-Ro52 (SS-A) antibodies cross-react with laminin--a role in the pathogenesis of congenital heart block?Clin Exp Immunol1995; 99(3): 316–324.
27.
DornerTFeistEChaouiR, et al.Enhanced frequency of autoimmune congenital heart block in female offspring. Rheumatology1999; 38(4): 380–382.
28.
MorelNLévesqueKMaltretA, et al.Incidence, risk factors, and mortality of neonatal and late-onset dilated cardiomyopathy associated with cardiac neonatal lupus. Int J Cardiol2017; 248: 263–269.
29.
BuyonJPClancyRM. Neonatal Lupus: Review of Proposed Pathogenesis and Clinical Data from the US-based Research Registry for Neonatal Lupus. Autoimmunity2003; 36(1): 41–50.
30.
KobayashiRMiiSNakanoT, et al.Neonatal lupus erythematosus in Japan: a review of the literature. Autoimmun Rev2009; 8(6): 462–466.
31.
FrediMAndreoliLBaccoB, et al.First report of the Italian registry on immune-mediated congenital heart block (Lu.Ne registry). Front Cardiovasc Med2019; 6: 11.
32.
LeeSYSimJHParkYL, et al.Neonatal lupus erythematosus in South Korea: clinical and serologic features. J Clin Exp Dermatol Res2011; 2(3).
33.
Gryka-MartonMSzukiewiczDTeliga-CzajkowskaJ, et al.An overview of neonatal lupus with anti-Ro characteristics. Int J Mol Sci2021; 22(17).
34.
WeckerleCENiewoldTB. The unexplained female predominance of systemic lupus erythematosus: clues from genetic and cytokine studies. Clin Rev Allergy Immunol2011; 40(1): 42–49.
35.
IzmirlyPMCostedoat-ChalumeauNPisoniCN, et al.Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation2012; 126(1): 76–82.
36.
BarsalouJJaeggiELaskinCA, et al.Prenatal exposure to antimalarials decreases the risk of cardiac but not non-cardiac neonatal lupus: a single-centre cohort study. Rheumatology2017; 56(9): 1552–1559.
37.
IzmirlyPKimMFriedmanDM, et al.Hydroxychloroquine to prevent recurrent congenital heart block in fetuses of anti-SSA/Ro-positive mothers. J Am Coll Cardiol2020; 76(3): 292–302.
38.
SilvermanEDBuyonJLaxerRM, et al.Autoantibody response to the Ro/La particle may predict outcome in neonatal lupus erythematosus. Clin Exp Immunol1995; 100(3): 499–505.
39.
YukikoN. Immune responses to SS-A 52-kDa and 60-kDa proteins and to SS-B 50-kDa protein in mothers of infants with neonatal lupus erythematosus. Br J Dermatol2000; 142(5): 908–912.
40.
EronenMMiettinenAWalleT, et al.Relationship of maternal autoimmune response to clinical manifestations in children with congenital complete heart block. Acta Paediatr2004; 93(6): 803–809.
41.
TranHBMacardlePJHiscockJ, et al.Anti-La/SSB antibodies transported across the placenta bind apoptotic cells in fetal organs targeted in neonatal lupus. Arthritis Rheum2002; 46(6): 1572–1579.
NeimanARLeeLAWestonWL, et al.Cutaneous manifestations of neonatal lupus without heart block: characteristics of mothers and children enrolled in a national registry. J Pediatr2000; 137(5): 674–680.
JonesSK. The effects of hormonal and other stimuli on cell-surface Ro/SSA antigen expression by human keratinocytes in vitro: their possible role in the induction of cutaneous lupus lesions. Br J Dermatol1992; 126(6): 554–560.
46.
WallaceDJGudsoorkarVSWeismanMH, et al.New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat Rev Rheumatol2012; 8(9): 522–533.
47.
GuiducciCTripodoCGongM, et al.Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9. J Exp Med2010; 207(13): 2931–2942.
48.
FrancèsCCosnesADuhautP, et al.Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study. Arch Dermatol2012; 148(4): 479–484.
